WaelAHarbMD

Clinical Trials

• Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer Start of enrollment: 2008 Jan 01

  Completed

  Phase 2

• BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Start of enrollment: 2010 Jan 01

  Completed

  Phase 1, Phase 2

• PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations Start of enrollment: 2010 Feb 01

  Completed

  Phase 2

• Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Start of enrollment: 2011 Feb 09

  Completed

  Phase 2

• Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors Start of enrollment: 2011 Oct 01

  Completed

  Phase 1

• Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment Start of enrollment: 2012 Jan 01

  Completed

  Phase 1

• Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2012 Nov 01

  Completed

  Phase 2

• Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer Start of enrollment: 2013 Sep 06

  Completed

  Phase 1

• ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma Start of enrollment: 2014 Mar 01

  Active, not recruiting

  Phase 1, Phase 2

• Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors Start of enrollment: 2013 Oct 01

  Completed

  Phase 1

• A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer Start of enrollment: 2014 Mar 05

  Completed

  Phase 1

• Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. Start of enrollment: 2014 Jun 27

  Completed

  Phase 1

• A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis Start of enrollment: 2014 Jul 16

  Active, not recruiting

  Phase 1, Phase 2

• A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Start of enrollment: 2014 Sep 09

  Terminated

  Phase 2

• A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer Start of enrollment: 2015 Apr 15

  Completed

  Phase 1, Phase 2

• Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC Start of enrollment: 2017 Jun 29

  Terminated

  Phase 2

• Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors Start of enrollment: 2017 Nov 28

  Active, not recruiting

  Phase 1

• Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma Start of enrollment: 2019 Apr 16

  Completed

  Phase 1

• Join now to see all